Thierry Chatellier

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial

Yungan Tao, Anne Aupérin, Christian Sire et al. · Journal of Clinical Oncology · 2018 · 77 citations

Medicine, Oncology, Radiation Oncology +10

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Elvire Pons‐Tostivint, P. Hulo, V. Guardiolle et al. · Cancer Immunology Immunotherapy · 2023 · 23 citations · Full text

Medicine, Oncology, Pharmacology +7

Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients

Yungan Tao, Anne Aupérin, Christian Sire et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 16 citations

Medicine, Oncology, Radiation Oncology +7

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

Marco Tagliamento, Marie Morfouace, Charalambos Loizides et al. · npj Precision Oncology · 2024 · 16 citations · Full text

Medicine, Molecular Medicine, Oncology +17